AURA Oncodistinct trial at ASCO 2024
Jérémy Blanc presented survival data results from AURA trial: Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004) at American Society Of Clinical Oncology (ASCO) in Chicago, USA.
We would like to thank all those who contributed to this trial, our study chairs Nieves Martinez Chanza, Jérémy Blanc and Ahmad Awada, the Sponsor (Clinical Trials Support Unit from Institut Jules Bordet,Brussels), all our Investigators and their team and finally our precious patients. Many thanks !
📌 Special mention: Congratulations to Jeremy for his Merit Award from Conquer Cancer for his session at ASCO2024.
You can learn more on the AURA trial here 👇
https://lnkd.in/eStJ5Jb7
